Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals has announced the issuance of 15,000 ordinary fully paid securities, effective May 30, 2025. This move reflects the company’s ongoing efforts to enhance its capital structure and support its strategic initiatives in the biotechnology sector, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products for oncology and rare diseases. The company is known for its innovative approach in the field of radiopharmaceuticals, aiming to improve the detection and treatment of cancer.
Average Trading Volume: 1,612,530
Technical Sentiment Signal: Buy
Current Market Cap: A$8.81B
See more data about TLX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue